A Nature Communications study shows that loss of the SWI/SNF subunit SMARCD1 reprograms clear cell renal cell carcinoma mitochondria via a MAFF–MFN1 pathway. Importantly, the approved drug leflunomide reverses the chromatin-driven mitochondrial switch in preclinical experiments, pointing to a repurposing opportunity tied to a defined molecular mechanism.